Bayer

Lung
Biotech

Roivant’s $14M bet on Bayer’s inhaled hypertension med pays off

Roivant’s $14 million bet on a pulmonary hypertension drug from Bayer appears to have paid off as the inhaled med aced a phase 2 lung disease study.
James Waldron Sep 8, 2026 6:00am
Graphic image of an arrow nailing the bullseye of a target

AbCellera tops ‘most aggressive’ hopes, putting rivals on notice

Aug 10, 2026 8:24am
Illustration for Fierces Chutes Ladders feature showing a blue city skyline with executives making career moves o

Perrigo CEO ousted over ‘personal conduct’—Chutes & Ladders

Jun 12, 2026 8:30am
Bayer cross

Bayer scraps ph.1-stage hypertension, neuropathic pain drugs

May 12, 2026 5:07am
illustration of two people shaking hands for a merger or acquisitions deal

Bayer buys Perfuse in $2.4B deal for ph. 2 eye disease prospect

May 6, 2026 7:20am
Charming view of the seaside resort town of Kas in Turkey Romantic lighthouse at the entrance to the port and a paraglider f

Bayer radiology head takes top U.S. pharma spot—Chutes & Ladders

Apr 3, 2026 8:30am